07 Jan 2001

Eremfat® 150 (Eremfat® 150/-300/-450/-600 Filmtabletten) - Deutschland

Updated: 07 Jan 2001

Eremfat® 150 | -300 | -450 | -600; -Sirup; -i.v. 300 mg | -600 mg

Tuberkulose (in Komb. mit anderen Tuberkulosemitteln). Zur Kombinationsbehandl. bei Lepra u. Buruli ulcus (Erreger: Mycobacterium leprae, bzw. M. ulcerans). Meningokokken- Meningitis-Prophylaxe.

Eremfat® 150 Description, Presentation and Dosage

Eremfat® 150 Description

Eremfat® 150 Drug Class Description

Einzelstoffe

Eremfat® 150 Drug Description

1 Filmtbl. enth.: Rifampicin 150 mg/300 mg/450 mg/600 mg.

Eremfat® 150 Generic Name

Eremfat® 150/-300/-450/-600 Filmtabletten

Eremfat® 150 Presentation

Eremfat® 150 Presentation

Eremfat® 150/-300/-450/-600; -Sirup; -i.v. 300 mg/-600 mg

Eremfat® 150 Manufacturer

Fatol

Related Learning Zones

LAL-D Knowledge Centre

LAL-D Knowledge Centre

The Lysosomal Acid Lipase (LAL) Deficiency Knowledge Centre contains a range of accurate, informative clinical content for healthcare professionals. The disease awareness section presents epidemiology, pathophysiology and diagnosis information, among others. The treatment section details the drug characteristics, safety and efficacy of sebelipase alfa – the first and only licenced treatment for LAL deficiency. The resources section contains further clinical content including a video channel presenting expert opinions on diagnostic approach and current prognosis.

Developed by EPG Health Media (Europe) Ltd for epgonline.org, in collaboration and with content provided by Alexion Pharma GmbH

Type 2 Diabetes Knowledge Centre and CME

Type 2 Diabetes Knowledge Centre and CME

The Type 2 Diabetes Learning Zone comprises the Type 2 Diabetes Mellitus Knowledge Centre containing current epidemiology statistics, current diagnosis criteria from WHO and ADA, treatment options and latest guidelines; a Therapy Focus area compiling material on emerging insulin/incretin treatment combinations; and two free CME activities, which are the EACCME-accredited ‘Role of Newer Therapies for Type 2 Diabetes in Combination with Insulin’ (worth 1 CME credit) and ‘Best Practice in Type 2 Diabetes: Update on Incretin Therapies in Combination with Insulin’. 

Eremfat® 150 Dosage

Eremfat® 150 Adult Dosage

Poly(O-2-hydroxypropyl-O-methyl)cellulose, Croscarmellose-Natrium, Magnesiumstearat, Talkum, Farbstoffe: E 171, E 172, Crospovidon, Sorbitol.

Eremfat® 150 Child Dosage


Eremfat® Sirup Trockensirup
Zus.: 5 ml enth.: Rifampicin 100 mg.
Weit. Bestandteile: Saccharose 2,16 g, Natriumbenzoat (als Konservierungsmittel), Aromastoffe.

Eremfat® i.v. 300 mg/-600 mg Trockensubstanz u. Lösungsmittel
Zus.: 1 Inj.-Fl. enth.: Rifampicin-Natrium 308,2 mg mg/616,4 mg (entspr. 300 mg/600 mg Rifampicin).
Weit. Bestandteile: Natriumascorbat 5 mg/10 mg.

Eremfat® 150 Elderly Dosage

5 ml entspr. 0,18 BE.

Eremfat® 150 Precautions, Reactions and Contraindications

Eremfat® 150 Special Precautions

Eremfat® 150 Special Precautions

R 15

Eremfat® 150 Adverse Reactions

Eremfat® 150 Adverse Reactions

R 15

Related Drugs - Tropical Medicine

Back to top